Navigation Links
Independent Clinical Results Demonstrate Outstanding Effectiveness of INVOcell Process
Date:10/27/2010

DENVER and BEVERLY, Mass., Oct. 27 /PRNewswire-FirstCall/ -- INVO Bioscience, Inc. (OTC Bulletin Board: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced today that Dr. Elkin Lucena of the Columbian Fertility and Sterility Center (CECOLFES LTDA) in Bogota, Colombia presented the results of the Center's first 95 fertility treatment cycles utilizing INVO Bioscience's INVOcell for couples with fertility issues at the 66th Annual Meeting of the American Society of Reproductive Medicine (ASRM) in Denver.  

The presentation revealed that CECOLFES produced clinical pregnancy rates of 43% per INVOcell cycle and a 48% clinical pregnancy rate when an embryo has been transferred in the cycle. This outstanding effectiveness was achieved in cycles completed in women from ages 21 to 45. The clinical pregnancy rate for patients aged 40 and younger was 46%. According to the U.S. Center for Disease Control (CDC) current infertility treatments are in the same range of efficacy. The CECOLFES results also indicated that multiple pregnancies occurred in 10% of the patients in the study compared to 30% multiple pregnancies that occur in more traditional fertility treatment regimes. Multiple pregnancies can cause very serious and expensive complications.

Claude Ranoux, MD, MS, president and chief scientific officer for INVO Bioscience, Inc., commented, "We are delighted with the results presented by the Colombian Fertility and Sterility Center and Dr. Lucena. These results are consistent with our in-house data. It is important to note that in the INVOcell process significantly fewer eggs are recruited from patients, which decreases the risk of multiple births and reduces the number of premature births. Combining the comparative cost advantage of the INVOcell treatment versus current treatment regimes, and the ability to significantly reduce the occurrence of multiple pregnancies and their substantial incremental costs, positions INVOcell as an important therapy for infertility patients. The INVO procedure can generate outstanding results while significantly bringing down fertility treatment costs. We are very pleased with these results."

Dr. Ranoux continued, "The report of these results is an important development in the history of the INVOcell device and process.  The presentation of the positive results of this data at the prestigious ASRM Annual Meeting represents a powerful affirmation by one of the renowned pioneers in the fertility field, Dr. Lucena, as an effective, safe, and cost efficient technology. The INVO procedure will address a problem that affects millions of infertile patients worldwide. We look forward to leveraging this event as we continue our efforts to widely commercialize this revolutionary alternative for deserving patients in need of these life-fulfilling treatments."

INVOcell is CE Mark approved in Europe and Canada and conforms with all consumer health and safety requirements. INVOcell is currently marketed and sold in Austria, Canada, Cameroon, Columbia, Dominican Republic, Guatemala, Nicaragua, Pakistan, Panama, Peru, Spain, Togo, Turkey, and Venezuela.

About CECOLFES LTDA

The Colombian Fertility and Sterility Center - "CECOLFES LTDA." – is a private institution established in 1978 under the scientific leadership of Prof. Elkin Lucena, MD, BMR, with the corporate aim of offering to the community and, in particular, to the growing number of infertile couples, state-of-the-art scientific technologies in the area of assisted human reproduction.
For more information, please visit www.cecolfes.com/index.php?idioma=en

Dr. Elkin Lucena is a noted expert in the field of reproductive health and infertility. Dr. Lucena produced the first baby born by IVF (In Vitro Fertilization) in South America and he and his team continue to pioneer reproductive technologies throughout South America.

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

Private Securities Litigation Reform Act of 1995

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.Contact: Kathleen KarloffINVO Bioscience, Inc. 978-878-9505 ext 504 www.invobioscience.comEquiti-Trend Advisors800-953-3550
'/>"/>

SOURCE INVO Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
3. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
4. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
6. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
7. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
8. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Promise of Vicals CMV Vaccine Noted by Independent Experts
11. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a ... cells and other difficult to transfect cells, announces its launch of the PluriQ™ ... Gene Editing System is a complete system for culturing and transfecting human ...
Breaking Medicine News(10 mins):